News

The ongoing double-blind 48-week trial is evaluating TAF 10mg/elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg with Stribild in treatment-naïve adults. A comparable virologic response was observed at 24 weeks of therapy

Catalyst licenses North America rights to Firdapse, an orphan drug that is in the Phase III trial for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). According to the

Truppi in his new role is expected to increase business from US companies based in the Eastern half of North America, mainly focussing on Boston, Pennsylvania and New

Charles River, with the help of the acquisition, will provide research models and associated services for drug discovery and development in China. Charles River Laboratories chairman, president, and

The sale is part of Vion’s revised strategy to disinvest companies that are no longer part of the company’s core activities. Banner Pharmacaps manufactures proprietary softgel capsules for

Under the SC Proven brand, both the companies have launched the first product, ultra-primary human fibroblast cell line, which are believed to be starting material to generate human

The 4-in-1 nutrition shake, which is available in chocolate and vanilla flavors, includes the company’s proprietary Revigor ingredient and 13 grams of protein to help protect, preserve and

Spermatech, an early drug development company, identifies small molecules which can be developed into a non-hormonal male contraceptive. Dotmatics Platform will be used to manage and analyse data

The partnership will focus on developing the small molecule inhibitors as therapeutics to treat cancer in humans. TPP CEO Tom Brown said the agreement will allow the company